Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Getting great questions from patients with EGFR+ lung cancer about the MARIPOSA and MARIPOSA 2 studies after ELCC 25, and how they differ.
What else should we add to this table to make it more helpful?”
Related to this article:
MARIPOSA trial results presented at ELCC25 – BREAKING from Paris